---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-056605"
form_type: "8-K/A"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T17:38:36.585181+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics details CEO Flores' severance and CFO Diem's compensation

## Summary
- Flores receives 12 months base salary severance, COBRA reimbursement, and extended option exercise to 3 years.
- 80,100 unvested shares of restricted stock fully vest after 6-month advisory period.
- CFO Diem's base salary increased to $500,000 with 45% bonus target.
- Diem receives $500,000 RSU grant vesting 50% Nov 2023 and rest by Nov 2024 or performance milestone.
- Separation agreement includes non-disparagement and cooperation clauses.

## SEC filing metadata
- accession: 0001104659-23-056605
- form_type: 8-K/A
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465923056605/0001104659-23-056605-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465923056605/tm2314832d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-056605
- JSON: https://secwatch.observer/filing/0001104659-23-056605.json
- Plain text: https://secwatch.observer/filing/0001104659-23-056605.txt

## Key facts
- Executive change
  Osvaldo Flores departed as President and Chief Executive Officer at Century Therapeutics, Inc..
  - Action: stepped down
  - Role: President and Chief Executive Officer
  source text: Osvaldo Flores, Ph.D. stepped down as the President and Chief Executive Officer of the Company and as a member of the Board of Directors of the Company (the “Board”) effective April 11, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465923056605/0001104659-23-056605-index.htm
- Executive change
  Michael Diem was appointed as Chief Financial Officer at Century Therapeutics, Inc..
  - Action: promoted
  - Role: Chief Financial Officer
  source text: On April 11, 2023, the Board promoted Dr. Michael Diem to Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850119/000110465923056605/0001104659-23-056605-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.